The compensatory ERK5 activation occurred in a delayed fashion and was sensitive to a platelet-derived growth factor receptor (PDGFR) [37], whose upregulation, among that of other receptor tyrosine kinases, frequently contributes to MAPKi resistance in melanoma [122]. Here, MAPK7 is linked to melanoma.